Inozyme Pharma (INZY) Climbs 6.33% on June 22

Equities Staff  |

Inozyme Pharma Inc (NASDAQ: INZY) shares are up 6.33%, or $0.29 per share, as on 11:59:39 est today. After Opening the Day at $4.63, 65,429 shares of Inozyme Pharma have traded hands and the stock has moved between $5.00 and $4.24.  

Already the company has moved YTD 32.84%.

Inozyme Pharma anticipates its next earnings on 2022-08-11.

For technical charts, analysis, and more on Inozyme Pharma visit the company profile.

About Inozyme Pharma Inc

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through the company's in-depth understanding of the biological pathways involved in mineralization, company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. Inozyme is initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.

To get more information on Inozyme Pharma Inc and to follow the company's latest updates, you can visit the company's profile page here: Inozyme Pharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content